Ethicist appalled by Novartis’ medi raffle

Novartis has put parents of children up to two years of age suffering from the rare muscle-wasting disease SMA in a state of emergency of hope and anxiety. Because this year Novartis wants to raffle off 100 doses of the million-dollar gene therapy Zolgensma – in countries outside the USA where the therapy has not yet been approved.

The ethics professor Nikola Biller-Andorno (48) is horrified. Deciding by lot who should receive a promising drug for a serious illness is a very problematic concept, the director of the Institute for Biomedical Ethics at the University of Zurich told BLICK. “It feels a bit like playing with people’s lives or well-being,” she adds.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Never miss any important news. Subscribe to our newsletter.